Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL
Status:
Recruiting
Trial end date:
2021-11-27
Target enrollment:
Participant gender:
Summary
This multi-center study open-label trial will enroll a single cohort of relapsed/refractory
diffuse large B cell lymphoma (DLBCL) patients whom are ineligible for autologous stem cell
transplant (ASCT) due to 1) insensitivity to salvage chemotherapy, or 2) inability to
tolerate high-dose myeloablative chemotherapy. All patients will receive dual checkpoint
blocking antibody (DCBA) therapy with established doses currently being used in phase III
trials of ipilimumab (1mg/kg) and nivolumab (3mg/kg) given at three week intervals, two times
before, and two times following "immunotransplant" in which T cells (in whole PBMCs) are
cryopreserved and re-infused (adoptive T cell transfer or ATCT) following lymphodepleting
chemotherapy regimen, currently being employed in adoptive T cell therapies.